603259.SH
XD药明康
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 155.84
−4.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 48.2B | 45.5B | 39.2B | 40.3B | 39.4B |
| Cost of Revenue | 24.4B | 23.8B | 23.0B | 23.7B | 24.7B |
| Gross Profit | 23.8B | 21.7B | 16.3B | 16.6B | 14.7B |
| Operating Expenses | |||||
| R&D Expense | 1.2B | 1.1B | 1.2B | 1.4B | 1.6B |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 2.8B | 2.7B | 2.9B | 2.9B | 2.8B |
| Selling & Marketing Expense | 794.9M | 806.9M | 745.4M | 701.0M | 731.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 5.5B | 5.3B | 4.4B | 5.0B | 5.1B |
| Cost and Expenses | 29.9B | 29.1B | 27.3B | 28.7B | 29.8B |
| Operating Income (EBIT) | 25.3B | 23.9B | 11.6B | 11.9B | 10.7B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 25.2B | 23.9B | 11.5B | 11.8B | 10.6B |
| Income Tax Expense | 4.9B | 4.6B | 2.0B | 2.1B | 1.7B |
| Bottom Line | |||||
| Net Income | 20.1B | 19.2B | 9.5B | 9.6B | 8.8B |
| Earnings from Cont. Ops | 18.9B | 18.0B | 11.5B | 10.2B | 8.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 20.1B | 19.2B | 9.5B | 9.6B | 8.8B |
| Per Share | |||||
| Basic EPS | CN¥7.02 | CN¥6.70 | CN¥3.28 | CN¥3.27 | CN¥3.01 |
| Diluted EPS | CN¥7.02 | CN¥6.61 | CN¥3.26 | CN¥3.24 | CN¥2.82 |
| Revenue Per Share | CN¥16.49 | CN¥15.90 | CN¥13.62 | CN¥13.73 | CN¥13.44 |
| Shares | |||||
| Basic Shares Outstanding | 2.9B | 2.9B | 2.9B | 2.9B | 2.9B |
| Diluted Shares Outstanding | 2.9B | 2.9B | 2.9B | 2.9B | 2.9B |
| Profitability Metrics | |||||
| EBITDA | — | 27.3B | 14.3B | 14.2B | 12.4B |
| D&A | — | 3.4B | 2.8B | 2.3B | 1.7B |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026